Quarterly ResultMay 7, 2026, 07:52 AM
Ascendis Pharma YUVIWEL® FDA Approved; Q1 Net Profit €629.3M
AI Summary
Ascendis Pharma reported a significant financial turnaround in Q1 2026, driven by the U.S. FDA Accelerated Approval of YUVIWEL® (navepegritide) and the recognition of substantial deferred tax assets. The company posted a net profit of €629.3 million, reversing a prior-year loss, with revenue more than doubling to €246.6 million. Additionally, Ascendis Pharma initiated a $120 million share repurchase program, buying back $60.0 million in shares during the quarter.
Key Highlights
- YUVIWEL® (navepegritide) received U.S. FDA Accelerated Approval on February 27, 2026.
- Q1 2026 net profit was €629.3 million, a significant turnaround from a €94.6 million loss in Q1 2025.
- Revenue for Q1 2026 increased 144% year-over-year to €246.6 million.
- Basic earnings per share for Q1 2026 was €10.20, compared to a €1.58 loss per share in Q1 2025.
- Recognized €679.6 million in deferred tax assets, significantly impacting net profit.
- Board authorized a $120 million share repurchase program on January 9, 2026.
- Repurchased 254,027 ordinary shares for $60.0 million in March 2026.
- Reversed €10.9 million in inventory write-downs due to YUVIWEL® marketing approval.